QUCY Quantum Cyber N.V.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1874252 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-0.2%
TTM net income YoY18.0%
TTM EPS YoY66.2%
Revenue 3-yr CAGR15.7%
Net income 3-yr CAGR—
Margins
Gross margin64.3%
Operating margin-2,099.9%
Net margin-2,416.0%
FCF margin-1,950.2%
EBITDA margin-2,022.0%
Returns
ROE-462.0%
ROA-149.4%
ROIC (approx.)—
Asset turnover0.06x
Leverage & solvency
Liabilities / assets55.6%
Debt / equity0.00x
Current ratio1.30x
Interest coverage-19.85x
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-29.5%
Payout ratio—
Capex / revenue11.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2023Q4*2023-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $966,833 | — | — | — | — | — | — | $214,761 |
| Cost of revenue | $873,243 | — | — | — | — | — | — | $80,027 |
| Gross profit | $93,590 | — | — | — | — | — | — | $134,734 |
| R&D expense | — | $4.55M | $59,300 | — | — | $101,278 | $88,748 | $2.00M |
| SG&A expense | $2.93M | $3.88M | $2.12M | $2.25M | $692,590 | $670,950 | $1.50M | $3.78M |
| Operating income | -$4.86M | -$9.89M | -$2.46M | -$10.60M | -$1.17M | -$1.63M | -$2.75M | -$6.59M |
| Interest expense | $3,146 | $7,208 | $15,175 | $239,641 | $42,880 | $60,403 | $30,534 | $478,891 |
| Pretax income | -$4.92M | -$10.07M | -$2.49M | -$10.55M | -$1.21M | -$1.68M | -$2.77M | -$5.18M |
| Net income | -$5.38M | -$11.02M | -$5.08M | -$4.81M | -$2.92M | -$3.48M | -$5.00M | -$5.18M |
| EBITDA | -$4.84M | -$9.89M | -$2.41M | -$10.64M | -$503,859 | -$1.79M | -$2.58M | -$6.39M |
| EPS (basic) | -0.08 | -0.62 | -0.43 | — | -0.42 | -0.80 | -1.46 | — |
| EPS (diluted) | -0.08 | -0.62 | -0.43 | — | -0.42 | -0.80 | -1.46 | — |
| Weighted avg. shares (diluted) | 63.68M | 17.85M | 11.80M | — | 7.00M | 4.37M | 3.43M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.90M | $13.40M | $4.70M | $701,602 | $1.03M | $1.71M | $1.69M | $7.07M |
| Short-term investments | $132,003 | — | — | — | — | — | — | — |
| Receivables | $643,386 | — | — | — | — | $40,122 | — | $93,555 |
| Inventory | $929,606 | — | — | $216,888 | — | $503,053 | — | $613,638 |
| Current assets | $8.65M | $16.69M | $6.60M | $4.21M | — | $3.09M | — | $8.98M |
| PP&E, net | $2.78M | $136,799 | — | $1.09M | — | $1.39M | — | $1.70M |
| Goodwill | $534,000 | — | — | — | — | — | — | — |
| Intangibles | $6.45M | $6.54M | $1.11M | $1.11M | — | $4.01M | — | $3.39M |
| Total assets | $18.77M | $23.37M | $7.72M | $5.33M | — | $9.80M | — | $15.41M |
| Current liabilities | $2.32M | $3.00M | $3.13M | $4.69M | — | $5.99M | — | $9.24M |
| Short-term debt | — | — | — | $956,902 | — | — | — | — |
| Total liabilities | $2.61M | $3.00M | $3.13M | $4.69M | — | $7.28M | — | $12.16M |
| Shareholders' equity | $16.15M | $20.36M | $4.59M | $641,600 | $2.67M | $2.61M | $2.38M | $3.35M |
| Shares outstanding | 87.22M | 9.78M | 9.78M | 9.78M | — | — | — | — |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.26M | -$7.19M | -$2.71M | -$1.71M | -$2.75M | -$2.57M | -$3.94M | -$4.66M |
| Capital expenditure | $0 | $136,799 | $658 | $0 | $93 | -$93 | $1,216 | $161,808 |
| Free cash flow | -$4.26M | -$7.33M | -$2.71M | -$1.71M | -$2.76M | -$2.57M | -$3.94M | -$4.82M |
| Investing cash flow | -$4.28M | $913,201 | -$650,658 | -$235,359 | -$346,919 | -$253,081 | -$198,042 | -$261,808 |
| Financing cash flow | -$62,138 | $14.96M | $7.27M | $1.78M | $2.31M | $3.03M | -$356,958 | $3.47M |
| Depreciation & amortization | $20,749 | -$2,294 | $58,000 | -$47,156 | $662,876 | -$160,849 | $160,849 | $204,470 |
| Stock-based compensation | $282,399 | -$528,922 | $176,531 | $226,984 | $228,822 | $487,827 | $856,286 | $818,991 |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.